申请人:The Upjohn Company
公开号:US03991070A1
公开(公告)日:1976-11-09
Preparing 1-halo-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines by reacting an N-halosuccinimide with a 2-[3-(phthalimidomethyl)triazolyl]benzophenone to form the 2-[5-halo-3-(phthalimidomethyl)triazolyl] benzophenone and reacting the 2-[5-halo-3-(phthalimidomethyl)triazol-4-yl]benzophenone with hydrazine or a primary amine in an organic liquid solvent medium at 25.degree. to 100.degree. C. The products of the process have CNS tranquilizer and sedative properties but are also of interest for use as intermediates to prepare 2,4-dihydro-6-phenyl-1H-s-triazolo[4,3-a] [1,4]benzodiazepin-1-ones which are of clinical interest for their CNS tranquilizer, sedative and anti-depressant drug use properties in mammalian animals including humans.
通过将N-卤代琥珀酰亚胺与2-[3-(邻苯二甲酰亚胺基)三唑基]苯基酮反应,制备1-卤代-6-苯基-4H-s-三唑并[4,3-a][1,4]苯二氮平。该反应生成2-[5-卤代-3-(邻苯二甲酰亚胺基)三唑基]苯基酮,然后将2-[5-卤代-3-(邻苯二甲酰亚胺基)三唑-4-基]苯基酮与肼或一级胺在有机液体溶剂介质中在25°C至100°C反应。该过程的产物具有中枢神经系统镇静剂和镇静剂特性,但也具有作为中间体制备2,4-二氢-6-苯基-1H-s-三唑并[4,3-a][1,4]苯二氮平的兴趣,这些化合物在哺乳动物动物包括人类的中枢神经系统镇静剂,镇静剂和抗抑郁药物使用特性方面具有临床兴趣。